1,284 Analyzed Papers
42,910 FDA Side-Effect Signals
148 Active Global Trials
$15.2 B Global Alopecia Market

Annual Research & Trial Trends

NCBI Live

Research Share by MoA Target

ChEMBL DB

Live Drug Repurposing Candidates

PubMed & BioRxiv Hair Loss Fact Analysis

AI collects research papers and provides 3-line fact summaries, targets, and key molecules.

FDA Adverse Event (FAERS) & Signal Analysis

Tracks hypertrichosis (hair growth) side-effect signals for drug repurposing.

Top Hypertrichosis Report Drugs (Repurposing Candidates)

Generic Name Original Indication Hypertrichosis Cases Repurposing Potential Fact Analysis

FDA Side-Effect Signal Comparison

Global Clinical Trials Pipeline

Tracking 148 active global clinical trials on Alopecia (ClinicalTrials.gov).

NCT ID Trial Title Sponsor / Pharma Phase Target / Therapy Status

Target Protein & Compound 3D Explorer

Integrated public facts from ChEMBL, UniProt, and AlphaFold 3D structure predictions.

AlphaFold & ChEMBL 3D Protein-Molecule Simulation

● 3D Interactive (Drag & Rotate) | AlphaFold pLDDT: 94.2

AR (Androgen Receptor) - 3D PDB: 2AMA

AlphaFold predicted 3D structure of Androgen Receptor. Highlighting the 3D binding pocket inducing TGF-β1 hair follicle miniaturization.

ChEMBL Compound CHEMBL1201 (Finasteride)
Binding Energetics (IC50) 12.4 nM (Strong)
AR (Androgen Receptor)
Inhibitor Required
Androgen Receptor (5α-reductase Follicular Atrophy)
💡 Biological Fact: Binds DHT to induce TGF-β1 in dermal papilla cells. Inhibition extends follicle lifespan.
Skin Permeability (LogP): 3.2 (Excellent Absorption, 372Da)
Patent Freedom (FTO): Patent Expired (Free FTO)
IC50 Potency: Finasteride (12.4 nM) / Dutasteride (0.5 nM)
GSK-3β / Wnt Path
Activator Required
Glycogen Synthase Kinase 3β (Stem Cell Regen)
💡 Biological Fact: Blocking GSK-3β accumulates β-catenin to trigger Telogen to Anagen transition.
Skin Permeability (LogP): 2.8 (Topical Formulation Fits)
Patent Freedom (FTO): New Use Patent Filing Area
IC50 Potency: Valproate Deriv (8.2 nM) / CHIR-99021 (9.8 nM)
CRTH2 (PTGDR2)
Inhibitor Required
Prostaglandin D2 Receptor 2 (Inflammatory Atrophy)
💡 Biological Fact: PGD2 is 3x higher in balding scalp. Blocking CRTH2 prevents follicle miniaturization.
Skin Permeability (LogP): 3.9 (Lipophilic Scalp Lotion Fit)
Patent Freedom (FTO): Repurposing Opportunity Available
IC50 Potency: Ramatroban (24.1 nM) / Setipiprant (67.0 nM)

Real-Time Fact Alert Engine

Automated AI notifications triggered on new PubMed papers, FDA signals, or ClinicalTrials.

Register New Fact Alert Keyword

Active Subscription Alert Feeds

Keyword Target DB Channel Latest Captured Fact Status
Wnt/β-catenin PubMed, ClinicalTrials Email (Daily) PMID: 38912041 New Paper Captured Active Monitoring
JAK3 Inhibitor OpenFDA, ClinicalTrials Slack Webhook Pfizer Phase 3 Status Updated Active Monitoring

FollicleIQ SaaS Subscription Tiers

100% Fact Automation Solutions for Researchers, Cosmetic R&D, and Beauty Enterprises

Free Fact Trial

Starter Fact

$0 / mo

Basic alopecia papers & FDA side-effect fact search trial

  • PubMed Basic Search (50/mo)
  • OpenFDA Major Side-Effects
  • No Real-Time Alerts
  • No PDF/Excel Export

Researcher Pro

$49 / mo

Tailored plan for bio researchers and dermatologists

  • Unlimited 360° Fact Search
  • AlphaFold 3D Explorer & Real-Time Alerts
  • 10 PDF B2B Report Exports / mo
  • 100% PMID/NCT Direct Fact Links
Enterprise B2B Tier

Corporate Enterprise

$299 / mo

For Pharma, Biotech, and Cosmeceutical R&D Teams

  • Multi-User Shared Workspace
  • Unlimited Real-Time Alerts (Slack/Email)
  • Unlimited PDF & Excel Raw Data Export
  • Drug Repurposing Full Access

Automated B2B Fact Report Generator

Generate verified fact briefing reports based on public database evidence for cosmetic R&D and labs.

Custom B2B Report Settings

Report Live Preview (Fact Summary Sample)